Brief: Calithera Expands Oncology Pipeline With Acquisition Of Two Clinical-Stage Assets From Takeda Pharmaceuticals

Calithera Biosciences

18/10/2021 21:19

Oct 18 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA EXPANDS ONCOLOGY PIPELINE WITH ACQUISITION OF
TWO
CLINICAL-STAGE ASSETS FROM TAKEDA PHARMACEUTICALS
    * CALITHERA BIOSCIENCES INC - CALITHERA WILL INITIATE PHASE
2
CLINICAL TRIALS OF SAPANISERTIB AND MIVAVOTINIB IN 2022
    * CALITHERA BIOSCIENCES INC - TORC 1/2 INHIBITOR
SAPANISERTIB AND
SYK INHIBITOR MIVAVOTINIB STRENGTHEN COMPANY'S PRECISION
ONCOLOGY PIPELINE
    * CALITHERA - TERMS OF TRANSACTION INCLUDE UPFRONT CASH
PAYMENT TO
TAKEDA OF $10 MILLION AND $35 MILLION ISSUED TO TAKEDA IN
CALITHERA SERIES A PREFERRED STOCK
    * CALITHERA BIOSCIENCES INC - TAKEDA WILL BE ELIGIBLE TO
RECEIVE
FROM CALITHERA CLINICAL DEVELOPMENT, REGULATORY AND SALES
MILESTONE PAYMENTS ACROSS BOTH PROGRAMS.
    * CALITHERA BIOSCIENCES INC - WILL PAY TIERED ROYALTIES OF
HIGH
SINGLE-DIGITS TO LOW TEENS ON FUTURE NET SALES SHOULD CANDIDATES
ACHIEVE APPROVALS

Source text for Eikon:  ID:nGNX4YwjP1 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))